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Objective: The aim of the study is to evaluate the clinical and economic impact of introducing 
a rocuronium–neostigmine–sugammadex strategy into a cisatracurium–neostigmine regimen 
for neuromuscular block (NMB) management.
Methods: We conducted a retrospective analysis of clinical outcomes and cost-effectiveness 
in five operating rooms at University Hospital of Padova. A clinical outcome evaluation after 
sugammadex administration as first-choice reversal drug in selected patients (rocuronium–
sugammadex) and as rescue therapy after neostigmine reversal (rocuronium–neostigmine–
sugammadex) compared to control was performed. A cost-analysis of NMB management 
accompanying the introduction of a rocuronium–neostigmine–sugammadex strategy into a 
cisatracurium–neostigmine regimen was carried out. To such purpose, two periods were com-
pared: 2011–2012, without sugammadex available; 2013–2014, with sugammadex available. 
A subsequent analysis was performed to evaluate if sugammadex replacing neostigmine as first 
choice reversal drug is cost-effective.
Results: The introduction of a rocuronium–neostigmine–sugammadex strategy into a 
 cisatracurium–neostigmine regimen reduced the average cost of NMB management by 36%, from 
€20.8/case to €13.3/case. Patients receiving sugammadex as a first-choice reversal drug (3%) 
exhibited significantly better train-of-four ratios at extubation (P,0.001) and were discharged 
to the surgical ward (P,0.001) more rapidly than controls. The cost-saving of sugammadex as 
first-choice reversal drug has been estimated to be €2.9/case. Patients receiving sugammadex 
as rescue therapy after neostigmine reversal (3.2%) showed no difference in time to discharge 
to the surgical ward (P=0.44) compared to controls. No unplanned intensive care unit (ICU) 
admissions with rocuronium–neostigmine–sugammadex strategy were observed. The potential 
economic benefit in avoiding postoperative residual curarization (PORC)-related ICU admission 
in the 2013–2014 period was estimated at an average value of €13,548 (€9,316–€23,845).
Conclusion: Sugammadex eliminated PORC and associated morbidities. In our center, sugam-
madex reduced the costs of NMB management and promoted rapid turnover of patients in operat-
ing rooms, with total cost-effectiveness that counteracts the disadvantages of its high cost.
Keywords: neuromuscular blockade; neuromuscular blocking agents; rocuronium; sugam-
madex; postoperative residual curarization; cost-benefit analysis.
Introduction
Neuromuscular blocking agents (NMBAs) are routinely used worldwide as part of a 
modern concept of balanced anesthesia. Rocuronium, an aminosteroid NMBA, and 
cisatracurium, a NMBA of the benzylisoquinoline family, are two common interme-
diate-duration NMBAs whose pharmacokinetic properties make them suitable for 
administration by either bolus or continuous infusion.1 Rocuronium features a rapid 
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onset of action.2 When a rapid induction of NMB is required, 
rocuronium 1–1.2 mg/kg may be substitutive of succinylcho-
line, which is effective, but has a wide range of potentially 
dangerous adverse effects, including death.3 Cisatracurium 
has an organ-independent metabolism since it is (at physi-
ological pH and temperature) rapidly degraded by Hoffmann 
elimination in plasma and tissues.4 This allows to limit the 
variability in duration of effect of cisatracurium,2 particularly 
in the presence of kidney or liver disease, and after continuous 
infusion in case of prolonged surgical procedure.1
Acetylcholinesterase inhibitors, such as neostigmine, are 
generally administered to hasten recovery from NMB and 
reduce the likelihood of postoperative residual curarization 
(PORC)5,6 that may occur with any NMBAs.1,5 PORC can 
result in potentially fatal adverse respiratory events (AREs), 
and, therefore, represents a clinically relevant problem.5,6 
Administering sugammadex, a modified γ-cyclodextrin that 
encapsulates and inactivates unbound aminosteroid NMBA, 
but not benzylisoquinoline NMBA, is emerging as a more 
favorable approach to achieving full reversal of NMB than 
neostigmine.3,7 Sugammadex has been approved for a quick 
and predictable reversal of moderate and profound NMB at 
doses of 2 and 4 mg/kg, respectively,8,9 and for immediate 
reversal at a dose of 16 mg/kg after the administration of 
1.2 mg/kg rocuronium.10 However, the cost of sugammadex 
has so far hindered its progress of becoming a widely used 
alternative to neostigmine.11 The potential advantage for 
the health system associated with the routine use of sugam-
madex has been demonstrated through cost-effectiveness 
analyses.12–14 However, there are no reports of a cost analysis 
of sugammadex use in clinical practice that considered the 
outcomes of treated patients, the real costs, and the potential 
benefits for the health system.3
Therefore, we performed a retrospective analysis of NMB 
management that examined the clinical and economic impact 
of introducing a rocuronium plus neostigmine and sugam-
madex strategy into a regimen based mainly on cisatracurium 
plus neostigmine.
Materials and methods
The study was approved by the Ethics Committee for  Clinical 
Research of Padova, which waived the requirement to obtain 
patient’s written informed consent. It was performed in five 
operating rooms (ORs) at University Hospital of Padova. 
These ORs have more than 8 hours of cases each workday. 
Abdominal surgery was the most frequently performed 
procedure.
introduction of sugammadex in our center
Given its cost, the Hospital Pharmacy approved (January 1, 
2013) the use of sugammadex for reversal of rocuromium-
induced NMB under quantitative neuromuscular monitoring 
only in select patients who were judged to have an increased 
risk of complications with reversal of NMB by neostigmine 
(“preventive” use): elderly patients; patients with morbid obe-
sity; patients presenting neurologic impairment, neuromus-
cular, respiratory, cardiac, kidney (with creatinine clearance 
[CrCl] .30 mL/min), and liver disease; patients with difficult 
airway management; and patients with contraindications to 
neostigmine plus atropine.3,15
Sugammadex was also approved for use as rescue therapy 
in two situations: “emergency use”, for rapid reversal of high 
dose rocuronium-induced NMB in case of “cannot venti-
late, cannot intubate” (CVCI) situation and “curative” use, 
for treatment of any PORC-related AREs after reversal of 
rocuronium-induced NMB with neostigmine,16,17 with PORC 
defined as a train-of-four (TOF) ratio ,0.9.5 PORC-related 
AREs were defined as difficult weaning from mechanical 
ventilation after general anesthesia with NMB and, after 
tracheal extubation, any critical respiratory event during the 
early postoperative period.6
Outcome evaluation
An evaluation of outcomes of sugammadex use in the 
2013–2014 period was carried out. All treated patients in 
both the “preventive” and “curative” group were matched 
with controls for comparison. The controls were chosen 
from patients with similar clinical characteristics in whom 
 rocuronium-induced NMB was reversed with neostigmine 
and who did not receive sugammadex. Both cases and 
controls were chosen from patients who underwent surgery, 
between 8 am and 8 pm, Monday through Friday, from 
 January 1, 2013 to December 31, 2014.
All patients received inhalational or intravenous anesthe-
sia and NMB with quantitative neuromuscular monitoring. At 
the time of tracheal extubation, the TOF ratio was measured 
and recorded. Patients were categorized into one of three 
groups based on the TOF ratio: acceptable neuromuscular 
recovery, TOF ratio $0.9; mild-to-moderate NMB, TOF ratio 
0.7 and 0.9; and severe NMB, TOF ratio ,0.7.6
In “curative” use patients, sugammadex was administered 
to treat PORC-related AREs occurring after the reversal 
of rocuronium-induced NMB with neostigmine and for 
which muscle relaxant antagonism was judged necessary. 
All PORC-related AREs were identified by an anesthetist in 
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the OR or a nurse in the recovery room (RR). For those that 
occurred in the RR, an anesthetist examined the patient to 
confirm a PORC-related ARE.6
Reports sent to the Hospital Pharmacy to justify sug-
ammadex use, the anesthesia records, and our information 
system’s computer database were used to retrieve data about 
patients and controls.
The pharmacoeconomic evaluation of 
sugammadex use
The pharmacoeconomic evaluation involved two aspects: 
cost-analysis of NMB management accompanying the intro-
duction of a rocuronium–neostigmine–sugammadex strategy 
into a cisatracurium–neostigmine regimen and estimation of 
the economic benefits of using sugammadex as first choice 
reversal drug.
costs analysis of nMB management
For the cost-analysis of NMB management, two periods 
were considered: January 1, 2011 to December 31, 2012 
(before the introduction of sugammadex) and January 1, 
2013 to December 31, 2014 (after the introduction of 
sugammadex).
Data about the type of anesthesia were collected from the 
surgical information system’s computer database and clas-
sified as general anesthesia with NMB, general anesthesia 
without NMB, and regional anesthesia (without NMB).
Data about the cost of drugs used for NMB management 
were retrieved from the Hospital Pharmacy, whose personnel 
tracked drug costs electronically. As the ORs at University 
Hospital of Padova are allocated a specific cost center num-
ber, we were able to retrieve data on the costs of drugs used 
exclusively in the ORs involved in this study. For each drug, 
the unit price was considered. The total costs of drugs used 
for NMB management were calculated by multiplying each 
drug cost by the number of vials used. The total costs were 
also compared for the two time periods.
Economic benefits of using sugammadex as first-
choice reversal drug
Two factors were considered for estimation of economic 
benefits: the difference in minutes between sugammadex and 
neostigmine with respect to the time until a complete recovery 
from NMB (TOF ratio $0.9) and the estimated costs of OR, 
and OR and RR staffs per minute using a validated model.13,14 
With regard to the first factor, two previous randomized 
controlled trials comparing sugammadex to neostigmine 
for reversing moderate and deep NMB were considered for 
evaluating the time of complete recovery from NMB.18,19 
With regard to the second factor, the estimated OR cost was 
based on the average cost of an OR (comprehensive of OR 
staff and material costs) at the University Hospital of Padova. 
The estimated OR staff cost was calculated assuming that 
the OR staff comprised two consultant surgeons, a consultant 
anesthetist, and three nurses. The estimated RR staff cost 
was calculated by assuming that the RR staff comprised 
one nurse. All costs were expressed in Euros 2015 (€). The 
potential gain in using sugammadex instead of neostigmine 
as first choice reversal drug was obtained by multiplying the 
time difference in minutes for the costs of OR, and OR and 
RR staffs. Costs of using sugammadex as rescue therapy and 
cost of neostigmine avoided were excluded in this analysis. 
A cost-saving analysis was then performed considering the 
cost of drugs used and the economic benefits.
Patients transferred from ORs to the intensive care unit 
(ICU) in the two periods (2011–2012 vs 2013–2014) were 
screened for the cause of ICU admission. Only patients admit-
ted because of a PORC were considered for the economic 
assessment of the impact on unplanned ICU admissions by 
the introduction of sugammadex. The estimated cost of ICU 
admission was obtained from previously published data20,21 
and adjusted to 2015 using the coefficient of conversion pro-
duced by ISTAT.22 This value corresponds to the average cost 
of a 1 day of ICU stay at University Hospital of Padova.23
statistical analysis
Data regarding surgery and costs are presented as totals and 
analyzed with chi-square test. For “preventive” and “curative” 
use of sugammadex, continuous data are reported as means 
(± standard deviation) and compared using the Student’s t-test. 
Categorical data are reported as the absolute number with 
percentages and compared with the chi-square test or Fisher’s 
exact test. Linear correlation analysis was used to estimate the 
association between the NMBA administered and presence 
of PORC-related AREs. Kaplan–Meier estimate-of-survival 
curves were used to determine the cumulative probability of 
delayed discharge from the OR to the surgical ward after 1 hour. 
Curves for the two groups were compared using the log-rank 
test. A P-value ,0.05 was considered statistically significant.
Results
Outcome
Patients undergoing general anesthesia with NMB who 
received sugammadex for “preventive” use were 3% of the 
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total cases (128 of 4,282 [total cases]) (Table 1). The treated 
group showed a better TOF ratio at extubation (P,0.001) 
and a more rapid discharge to the surgical ward than controls 
(P,0.001) (Table 1).
In eight cases, sugammadex was used for reversal of NMB 
at the end of surgery because of difficult airway manage-
ment at induction of anesthesia. In two cases, sugammadex 
was successfully used intraoperatively as rescue therapy for 
immediate reversal of a high-dose rocuronium-induced NMB 
for CVCI situation.
Patients undergoing general anesthesia with rocuronium-
induced NMB who received sugammadex for treatment of 
PORC-related AREs (“curative” use) were 3.2% of the cases 
(96 of 3,017 [cases treated with rocuronium]) (Table 2). 
PORC-related AREs included both difficult weaning (2% 
of cases) and postextubation AREs (1.2% of cases). The 
treated group showed a worse TOF ratio at the end of surgery 
than controls (Table 2). In the treated group, the occurrence 
of an ARE was significantly associated with longer surgi-
cal procedures (P,0.001), higher dosage of rocuronium 
(P,0.001), repeated doses of rocuronium (P,0.001), and 
shorter time between the last dose of rocuronium and tracheal 
extubation (P,0.001). The most frequent PORC-related 
AREs were difficult weaning from mechanical ventilation 
(60.4%), postextubation severe hypoxemia (19.8%), inability 
to breathe deeply (9.4%), upper airway obstruction (5.2%), 
signs of respiratory distress (3.1%), and respiratory failure 
requiring mask ventilation (2%). In the treated group, the 
PORC-related AREs did not prolong the RR stay, as the 
time to discharge from the RR was similar in the treated 
and control groups (Table 2). Sugammadex administration 
showed not only reduction of the probability of delayed dis-
charge to the surgical ward after 1 hour (Figure 1A and B) 
but also reduction in PORC-related ICU admissions. Ten 
PORC-related unplanned ICU admissions were registered in 
the 2011–2012 period and one in the 2013–2014 period. No 
unplanned ICU admissions with rocuronium–neostigmine–
sugammadex strategy were observed. No adverse drug 
reactions related to drugs used for NMB management were 
registered.
Table 1 Data for “preventive” use of sugammadex in high-risk patients and comparison with a control group
Treated groupa  
(128 patients)
Control groupb  
(128 patients)
P-value
sex (male/female), n (%) 60 (46.8)/68 (53.2) 57 (44.5)/71 (55.5) 0.8
age, years, mean ± sD 64±15 62±14 0.58
Weight, kg, mean ± sD 88±25 84±22 0.18
height, cm, mean ± sD 174±8 172±9 0.14
Reversal in patients with difficult airways, n (%)c 8 (6.2) 4 (3.1) 0.37
elderly subjects ($75 yr), n (%) 27 (21) 27 (21) 1.0
Morbid obesity (BMi .35), n (%) 36 (28.1) 36 (28.1) 1.0
respiratory disease, n (%)d 10 (7.8) 15 (11.7) 0.4
cardiac disease, n (%)e 14 (10.9) 19 (14.8) 0.45
Kidney disease, n (%)f 22 (17.1) 16 (12.5) 0.38
cirrhosis, n (%) 4 (3.1) 7 (5.4) 0.54
neuromuscular disease, n (%)g 3 (2.3) 4 (3.1) 1.0
contraindications to neostigmine/atropine, n (%) 4 (3.1) 0 (0) 0.12
Duration of surgery, min, mean ± sD 153±92 162±111 0.45
Duration of anesthesia, min, mean ± sD 174±98 192±121 0.17
inhalational anesthesia/TiVa, n (%)h 102 (79.6)/26 (20.4) 96 (75)/32 (25) 0.45
intraoperative analgesia (remifentanil/fentanyl), n (%) 91 (71.1)/37 (28.9) 84 (65.6)/44 (34.4) 0.42
Degree of nMB at extubation, n (%)i
 acceptable, n (%) 128 (100) 71 (55.5) ,0.001
 Mild-to-moderate, n (%) 0 (0) 41 (32) ,0.001
 severe, n (%) 0 (0) 16 (12.5) ,0.001
rr length of stay, min, mean ± sD 56±29 103±52 ,0.001
Notes: aadministration of sugammadex for reversal of rocuronium-induced nMB. badministration of neostigmine for reversal of rocuronium-induced nMB. creversal of 
NMB at the end of surgery in patients with difficult mask ventilation or endotracheal intubation observed at induction of anesthesia. dModerate-to-severe chronic obstructive 
pulmonary disease or asthma. eischemic heart disease, chronic heart failure. fmild-to-moderate renal impairment (crcl .30 ml/min) or kidney transplantation. gDuchenne 
muscular dystrophy, dermatomyositis, multiple sclerosis, myasthenia gravis. hDesflurane or sevoflurane anesthesia. iat the time of tracheal extubation and after reversal drugs 
administered (sugammadex in treated group and neostigmine in control group). Degree of nMB was rated as acceptable if recovery of the TOF ratio was $0.90, mild-to-
moderate if the TOF ratio was 0.7–0.90, or severe if the TOF ratio was ,0.70. student’s t-test and chi-square test or Fisher’s exact test were performed when appropriate. 
P,0.05 was considered statistically significant.
Abbreviations: BMi, body mass index; TiVa, total intravenous anesthesia with propofol; nMB, neuromuscular blockade; crcl, creatinine clearance; TOF, train-of-four; rr, 
recovery room; yr, year; min, minute; sD, standard deviation.
clinicoeconomics and Outcomes research 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
47
Economic benefit of sugammadex
A
100
50
0
100
50
0
0 100
P
ro
b
ab
ili
ty
 o
f 
d
el
ay
ed
d
is
ch
ar
g
e 
to
 s
u
rg
ic
al
 w
ar
d
 (
%
)
P
ro
b
ab
ili
ty
 o
f 
d
el
ay
ed
d
is
ch
ar
g
e 
to
 s
u
rg
ic
al
 w
ar
d
 (
%
)
200 300 0 100 200 25015050
Treated group
Control group
Time (min) Time (min)
P<0.001
(log-rank)
Treated group
Control group
P=0.16
(log-rank)
B
Figure 1 comparison of postoperative course between treated and control groups in 2013–2014 period.
Notes: cumulative probability of delayed discharge to the surgical ward after reversal of nMB at the end of general anesthesia with sugammadex for “preventive” use 
(A) and “curative” use (B) vs control. control group: reversal of nMB with neostigmine. Treated group: reversal of nMB with sugammadex. Kaplan–Meier estimate-of-
survival curves were obtained using graphPad software, inc., la Jolla, ca, Usa. P,0.05 was considered statistically significant.
Abbreviation: nMB, neuromuscular blockade; min, minutes.
Table 2 Data for “curative” use of sugammadex for adverse respiratory events and comparison with control group
AREs groupa  
(96 patients)
Control groupb  
(96 patients)
P-value
sex (male/female), n (%) 61 (63.6)/35 (36.4) 58 (60.4)/38 (39.6) 1.0
age, years, mean ± sD 67±9 65±11 0.23
Weight, kg, mean ± sD 71±10 73±9 0.74
height, cm, mean ± sD 175±8 177±8 0.25
asa physical status ii/iii/iV, n 39 (40.6)/47 (49)/10 (10.4) 46 (47.9)/43 (44.8)/7 (7.3) 0.38/0.66/0.61
Duration of surgery, min, mean ± sD 159±97 146±85 0.34
Duration of anesthesia, min, mean ± sD 190±106 174±92 0.27
long-standing surgery (.2 hours), n (%) 55 (57.3)/41 (42.7) 47 (49)/49 (51) 0.31
inhalational anesthesia/TiVa, n (%)c 71 (74)/25 (26) 76 (79.1)/20 (20.9) 0.55
intraoperative analgesia  
(remifentanil/fentanyl), n (%)
64 (66.6)/32 (33.4) 55 (57.3)/41 (42.7) 0.57
nMB-related data
 rocuronium total dose, mg 108±35 102±37 0.21
 Dose repeated, n (%) 75 (78.1) 71 (74.0) 0.61
 Time from last dose, min, mean ± sD 54±19 59±21 0.1
 neostigmine, mg, mean ± sD 3±0.6 3.2±0.9 0.12
Degree of nMB at evaluation, n (%)d
 acceptable, n (%) 8 (8.3) 73 (76) ,0.001
 Mild-to-moderate, n (%) 27 (28.1) 14 (14.6) 0.034
 severe, n (%) 61 (63.6) 9 (9.4) ,0.001
 rr length of stay, min, mean ± sD 66±27 70±25 0.44
Notes: aPatients with ares after reversal of nMB with neostigmine. bPatients without ares after reversal of nMB with neostigmine. cInhalational anesthesia: desflurane or 
sevoflurane anesthesia; TIVA. dDegree of nMB at evaluation: at the time of tracheal extubation (before sugammadex administration in treated group). Degree of nMB rated 
as acceptable if recovery of the TOF ratio was $0.90, mild-to-moderate if the TOF ratio was 0.7–0.90, or severe if the TOF ratio was ,0.70. TOF ratio was measured using 
acceleromyography (TOF-Watch®sX, Organon Teknik, ireland). student’s t-test and chi-square test or Fisher’s exact test were performed when appropriate. P,0.05 was 
considered statistically significant.
Abbreviations: are, adverse respiratory events; asa, american society of anesthesiologists; nMB, neuromuscular blockade; rr, recovery room; TiVa, total intravenous 
anesthesia with propofol; TOF, train-of-four; yr, year; min, minute; sD, standard deviation.
costs analysis of nMB management
Despite the overall number of procedures involving general 
anesthesia with NMB increasing significantly (P,0.0001) 
(Figure 2), the introduction of rocuronium–neostigmine–sug-
ammadex into a regimen based on cisatracurium–neostigmine 
as the main strategy for NMB management decreased the 
total costs of NMB management by 25% from 2011–2012 to 
2013–2014 (Figure 3). Although the costs per vial remained 
constant, the total costs for succinylcholine (P=0.0026) and 
cistracurium (P,0.0001) significantly decreased, whereas the 
costs for rocuronium (P,0.0001), sugammadex (P,0.0001), 
and neostigmine (P=0.0164) significantly increased over the 
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two time periods (Figure 2). The increased use of rocuronium 
(€1.85/vial), which is less expensive than cisatracurium 
(€6.25/vial), induced by introduction of sugammadex, allowed 
the reduction of the average cost of NMB management by 
36%, from €20.8/case to €13.3/case. The sugammadex cost 
for “preventive” use was €19,987 (272 vials), for “curative” 
use was €7,056 (96 vials), and for “emergency use” was €882 
(12 total vials). In the last situation, as recommended by the 
manufacturer, sugammadex 16 mg/kg was administered for 
immediate reversal of a high-dose rocuronium-induced NMB 
in two CICV situations.
Economic benefits of using sugammadex 
as first-choice reversal drug
The economic benefit in speeding the complete recovery from 
NMB and the discharge to surgical ward was estimated to be 
€6.6/min based on OR cost, and €3.72/min and €0.35/min 
based on OR and RR staffs, respectively (Table 3).
Considering that in the University Hospital of Padova the 
OR cost (€6.6/min) includes also the OR staff cost (€3.72/
min), the gain in shorter OR stay based on OR cost was esti-
mated to be €18,064 as obtained by calculating the difference 
between the loss of gain associated to neostigmine (€19,727) 
and sugammadex (€1,663) (Table 4 and Figure 4). Based on 
RR staff cost, the gain in shorter RR stay was estimated to 
be €2,105.6, considering the mean difference time of RR 
stay (Table 2). The total gain was then €20,169.6 which is 
derived from the sum of estimated gains in OR (€18,064) 
and in RR (€2,105.6). The final analysis, in which the cost of 
neostigmine for “preventive” use (€94) was excluded, showed 
a cost of €154.7/case and an estimated gain of €157.6/case, 
with a net cost-saving of €2.9/case.
The average cost of ICU stay was estimated to be 
€1,354.8/day (range from €931.6/day to €2384.5/day). Based 
on estimated cost of ICU stay, the economic benefit in avoid-
ing PORC-related ICU admission was estimated at €13,548 
(€9,316–€23,845).
Discussion
An NMB management based on rocuronium–neostigmine–
sugammadex strategy is less expensive than that based on 
cisatracurium–neostigmine regimen. Sugammadex was dem-
onstrated to increase safety in patients receiving a rocuronium-
induced NMB, avoiding PORC if given as the first-reversal 
drug in high-risk patients and allowing prompt treatment of 
PORC-related AREs occurring after administration of stan-
dard reversal drugs. Despite its cost, sugammadex showed 
resource savings to the hospital by speeding the recovery from 
NMB in the OR. It was also shown to potentially produce 
resource savings by reducing the rate of PORC, time spent 
in the RR, and rate of unplanned ICU admissions.
PORC following intraoperative NMBAs administration 
is common in the postoperative period, with rates rang-
ing from 26% to 64%.24,25 Residual effects of NMBAs are 
associated with an increased risk of AREs.6,26,27 The overall 
incidence of AREs (3.2%) observed in our study is within 
the range of 1.3%–6.9% reported in the literature.6,26 The 
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Figure 3 comparison of costs (in euro, €) for management of nMB after roc–
neo–sug strategy into a cis–neo regimen.
Notes: comparison of total costs of drugs used for nMB in 2011–2012 vs 
2013–2014: costs of suc (P=0.0026) and cis (P,0.0001) decreased, whereas costs 
of roc (P,0.0001), sug (P,0.0001), and neo (P=0.0026) increased. The costs 
were estimated as the number of vials used times for the cost of each drug vial, 
as provided by the Pharmacy of Padova hospital (suc: €0.22/vial; cis: €6.25/vial; 
roc: €1.85/vial; sug: €73.5/vial; neo: €0.126/vial). chi-square tests were performed 
using the chi2cdf function in MaTlaB version r2014b (The Mathworks; natick, Ma, 
Usa). *P,0.05 was considered statistically significant.
Abbreviations: nMB, neuromuscular blockade; suc, succinylcholine; cis, 
cistracurium; roc, rocuronium; sug, sugammadex; neo, neostigmine.
6,000
4,500
S
u
rg
ic
al
 p
ro
ce
d
u
re
s 
(n
)
3,000
1,500
0
2011–2012 2013–2014
RAGA without NMBGA with NMB
4,009
4,282
427657
1,098
589*
*
*
Figure 2 comparison of surgical procedures during two time different periods.
Notes: ga with nMB: total number of surgical procedures involving ga with 
nMB. ga without nMB: total number of surgical procedures performed under 
ga without nMB. ra: total number of surgical procedures performed under 
loco-regional anesthesia (without nMB). The number of procedures in all groups 
increased between 2011–2012 and 2013–2014: ga with nMB (P,0.0001); ga 
without nMB (P,0.0001), and ra (P=0.0071). chi-square tests were performed 
using the chi2cdf function in MaTlaB version r2014b (The Mathworks; natick, Ma, 
Usa). *P,0.05 was considered statistically significant.
Abbreviations: ga, general anesthesia; nMB, neuromuscular blockade; ra, 
regional anesthesia.
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incidence of postextubation AREs is greater than the 0.8% 
reported by Murphy et al,6 but close to the 1.3% that Rose 
et al26 reported in their study. Postoperative AREs are associ-
ated with increased postoperative morbidity and mortality, 
prolonged postanesthesia care unit (PACU) stay, or unantici-
pated admissions to the ICU.5,26,28 Strategies to reduce PORC 
include the use of short- or intermediate-duration NMBAs, 
neuromuscular monitoring, and reversal agents.5
The use of intermediate-duration NMBAs has been 
shown to reduce (albeit not eliminate) the risk of AREs.28,29 
Cisatracurium is purported to be advantageous over rocuro-
nium because of its organ-independent  metabolism.4,30,31 
However, a regimen based on cisatracurium for NMB 
does not completely eliminate the risk of PORC.5 In a 
randomized, controlled, double-blind, multicenter trial of 
338 patients, the incidence of PORC in patients  receiving 
cisatracurium was 57%, which was significantly (P,0.05) 
higher than the 44% incidence in those receiving rocuro-
nium.4 A wide variability in the rate of spontaneous recovery 
has been observed after a single dose of an intermediate-
duration NMBA, which can be prolonged by such factors 
as hypothermia, interactions with halogenated agents, and 
underlying diseases, and which may extend even longer 
than 2 hours.32 Furthermore, both a continuous infusion 
and repeated doses of these NMBAs are associated with 
an increased risk of PORC.1,4,33
The routine use of neuromuscular function monitoring has 
been previously shown to reduce the incidence of PORC.5,29,34 
However, quantitative monitoring of neuromuscular transmis-
sion does not entirely abolish the risk of PORC.28 Further-
more, it is not always used in clinical practice.35
Table 3 estimated costs associated with the operating room, operating room staff, and recovery room staff
Annual  
salary (€)
Workinga  
time
OR,b  
cost/min (€)
OR staff,  
cost/min (€)
RR staff, 
cost/min (€)
consultant surgeon seniorc 98,234 45 wk/38 h – 0.96 –
consultant surgeon juniord 82,116 45 wk/38 h – 0.80 –
consultant anesthetist 98,234 44 wk/38 h – 0.98 –
nurse D-level 36,186 45 wk/38 h – 0.35 –
nurse D-level 36,186 45 wk/38 h – 0.35 0.35
nurse Bs-level 29,370 45 wk/38 h – 0.28 –
Or cost for hour 400 – 6.6 – –
Total cost for minute (€) 6.6 3.72 0.35
Notes: aWorking time: effective working time of staff at Padova hospital bOr cost: all comprehensive average cost for hour of an Or in Padova hospital. csurgeon with 
.15 years of national health service activity. dsurgeon with 6–15 years of national health service activity. Personnel costs were based on annual salaries provided by the 
Personal administration of Padova hospital according with national health service.
Abbreviations: Or, operating room; rr, recovery room; wk, week; h, hours.
P
ro
d
u
ct
iv
it
y 
lo
ss
 (
�)
20,000
Sugammadex Neostigmine
15,000
10,000
5,000
0
939
Staff OR
11,120
19,727
1,663
*
*
*
*
Figure 4 estimation (in euro, €) of productivity (gain) loss with reversal of 
rocuronium-induced nMB by sugammadex administered for “preventive use” 
compared to neostigmine.
Notes: Chi-square tests were performed. Significance (*) was taken at P,0.05.
Abbreviation: nMB, neuromuscular blockade.
Table 4 comparison of productivity loss according to reversal 
strategy
Reversal  
time  
(min)
Cases  
(n)
Overall  
time  
(min)
Staff  
costs  
(€)
OR  
costs  
(€)
Sugammadex
Moderate nMB 1.718 93 158 588 1043
Deep nMB 2.719 35 94 350 620
Total 128 252 938 1,663
Neostigmine
Moderate nMB 13.718 93 1,274 4,740 8,408
Deep nMB 4919 35 1,715 6,380 11,319
Total 128 2,989 11,120 19,727
Notes: The reversal times to recovery to TOF ratio $0.9 multiplied by number 
of patients were used for estimation of overall time loss. The overall time loss 
multiplied by costs of Or staff and Or in Padova hospital was used for calculation 
of productivity (gain) loss. The mean times to recovery to TOF ratio $0.9 
(sugammadex vs neostigmine) were taken from illman et al18 for moderate nMB 
(1.7 vs 13.7 minutes) and from Jones et al19 for deep nMB (2.7 vs 49 minutes). 
Moderate nMB was observed in 93 patients, while deep nMB was observed in 
35 patients.
Abbreviations: Or, operating room; nMB, neuromuscular blockade; TOF, train-
of-four.
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The administration of reversal agents plays, then, an 
important role in reducing the risk of PORC.5,29,34 Tradition-
ally, acetylcholinesterase inhibitors, such as neostigmine, 
are used to hasten recovery from NMB. However, their 
efficacy is limited because of a ceiling effect, which limits 
their effectiveness when the NMB is profound.5,29 Moreover, 
using higher or repeated doses of neostigmine to improve 
neuromuscular recovery and reduce the rate of PORC may 
also be associated with increased postoperative respiratory 
morbidity.36 Because of its mechanism of action, sugam-
madex improves the quality and safety of NMB reversal 
in clinical practice.1,4,14,37 Sugammadex has been shown to 
reduce the incidence of PORC and AREs, and to shorten 
the time for discharge from the OR.7,29,38 The usefulness 
of sugammadex for treatment of AREs after neostigmine 
reversal has also been reported.17,39 Our data provide evi-
dence supporting the benefit of sugammadex in preventing 
PORC and associated morbidities,38 particularly in high-risk 
patients, such as those who are elderly or obese and those 
who have respiratory, cardiac, kidney, liver, or neuromus-
cular disease.5,40–43
The benefits associated with sugammadex have a cost, 
which is primarily related to the direct cost of the drug itself. 
However, in our economic evaluation, sugammadex may con-
tribute to overall cost-savings for the hospital in several ways. 
First, it reduced the cost of NMB management by requiring 
the use of rocuronium, which is three times less expensive 
than cisatracurium at the current list price in our hospital. 
Second, sugammadex allowed a rapid, safe, and complete 
recovery from NMB in high-risk patients.15,40–44 Third, sugam-
madex as rescue therapy after neostigmine reversal quickly 
resolved PORC-related AREs. Both these latter two aspects 
have clinical and economic implications. Prolonged time 
to extubation at the end of general anesthesia delays OR 
exit and slows OR workflow.45 Different surgical and anes-
thesiological factors may concur to a prolonged extubation 
that is regarded unfavorably by both anesthesiologists and 
surgeons.45,46 To such purpose, residual curarization showed to 
increase significantly the risk of delayed OR exit and PACU 
discharge.46 A proper NMB management may then play an 
important role in helping to avoid prolonged extubation time 
and delayed OR exit.42,47 Sugammadex has been shown to 
reduce the anesthesia time,42 and time for OR exit and PACU 
discharge.38,48 The economic benefits have been estimated to 
have a value of €6.6/min gained in OR (€3.72/min consider-
ing only the OR staff cost) and €0.35/min gained in the RR, 
with a net saving of €2.9/case. A recent pharmacoeconomic 
evaluation estimated that time saved in the OR has a value 
of £4.44/min, whereas time saved in the PACU has a value 
of £0.33/min, confirming that sugammadex 2 mg/kg (or 
4 mg/kg) is cost-effective for reversal of moderate (or deep) 
NMB induced by rocuronium13,14 and has the potential to 
increase the OR productivity with an associated economic 
benefit.21 However, the effort to reduce extubation time from 
the end of surgery has an economical advantage only if the 
OR represents a variable cost and not a fixed cost.45,49 This 
may be the case in which all (eg, .90%) ORs at a hospital 
have more than 8 hours of cases each workday. In such situ-
ations, there is a rationale to reduce the chance that tracheal 
extubation times will be prolonged.45,49
Another suggested benefit of sugammadex that was 
not investigated in this study is that scheduled surgical 
procedures may not be delayed or suspended because of 
unanticipated problems with the preceding surgery, such as 
prolonged reversal of NMB or PORC-related AREs requir-
ing postoperative care or unplanned ICU admission.13,14 The 
economic benefit may reach an average value of €1,354.8 
for each avoided day of ICU stay. Finally, by reducing 
morbidity and mortality associated with PORC or being 
unable to quickly reverse profound NMB with standard 
reversal drugs in a CVCI situation, sugammadex promotes 
improved quality and safety of anesthetic management that 
may not be quantifiable from an economic viewpoint, but 
is nevertheless highly desired.
The study has some limitations. First, it was performed in 
a single national center. The cost of drug use may be subject 
to variations among national hospitals. Furthermore, some 
aspects of the cost-analysis may not apply to other countries 
and different health-care systems.14 Second, the benefit of 
reduction in OR time may depend on the day of the week 
and the hours of cases in the OR in which the intervention is 
applied and may be lost in case of emergency room or ORs 
scheduled relatively empty in which ORs represent a fixed 
cost.45,50 Third, it is possible that sugammadex produces fur-
ther resource savings than those considered; however, there 
are no suitable data to provide a basis for such modeling, 
so these were not considered.14 Finally, an evaluation of the 
outcomes of patients undergoing general anesthesia with 
cisatracurium-induced NMB was not performed.14
Conclusion
In conclusion, sugammadex promotes a rapid turnover of 
patients in the OR, which is cost-effective and limits the 
disadvantage of its high cost. Through a rapid, predictable, 
and safe reversal of rocuronium-induced NMB, sugammadex 
minimizes the risk of PORC and its consequences.
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